313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
oleh: Xiaoyu Zhang, Sanjeev Kaul, Paul Moore, Jason Luke, Bartosz Chmielowski, Hedy Kindler, Francine Chen, George Blumenschein, Erika Hamilton, Shakeela Bahadur, Cesar Santa-Maria, Janine Koucheki, Jichao Sun, John Muth, Patrick Kaminker, Bradley Sumrow
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.